FOXM1-CD44 Signaling Is Critical for the Acquisition of Regorafenib Resistance in Human Liver Cancer Cells

Regorafenib is a multikinase inhibitor that was approved by the US Food and Drug administration in 2017. Cancer stem cells (CSCs) are a small subset of cancer-initiating cells that are thought to contribute to therapeutic resistance. The forkhead box protein M1 (FOXM1) plays an important role in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wuputra, Kenly, Hsiao, Pi-Jung, Chang, Wen-Tsan, Wu, Po-Hsuan, Chen, Lin-Ann, Huang, Jian-Wei, Su, Wen-Lung, Yang, Ya-Han, Wu, Deng-Chyang, Yokoyama, Kazunari K., Kuo, Kung-Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324640/
https://www.ncbi.nlm.nih.gov/pubmed/35887129
http://dx.doi.org/10.3390/ijms23147782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324640/
https://www.ncbi.nlm.nih.gov/pubmed/35887129
http://dx.doi.org/10.3390/ijms23147782

Ejemplares similares